The Journal of Headache and Pain Reports That electroCore’s Non-Invasive Vagus Nerve Stimulation (nVNS) Treatment is Effective in Migraines

Basking Ridge, NJ, July 17, 2015 --(PR.com)-- -- 65% of the study participants reported pain relief(1) by 2 hours after treatment, with 56% already reporting pain relief by one hour, and 35% were pain free by one hour

-- Authors stated that nVNS was safe, well tolerated and effective in many patients and may reduce medication overuse and medication associated adverse events

The study which is in the July edition of the The Journal of Headache and Pain(2) reports that electroCore’s nVNS treatment delivered by a gammaCore device was effective in reducing pain levels in more than 65 percent of the patients after two hours – the primary endpoint. Furthermore 65 percent achieved at least a 50 percent reduction in pain.

Migraine is a highly disabling condition with many of the treatments having both unpleasant side effects and a risk of generating medication overuse headache, which is a paradoxical increase in headache frequency and severity as a result of overuse of pain medication. GammaCore is seen as a new, easy to use treatment that patient self-administer with very few side effects. This study is one of a series, including double blind, sham controlled trials, demonstrating that nVNS is effective for many patients in both the treatment and prevention of cluster and migraine headaches.

This European multicentre study involved 48 patients (34 chronic and 14 high-frequency migraneurs) who experienced mild to moderate attacks. The patients self-treated a total of 131 attacks. Pain relief was reported for 51 percent of these attacks after two hours.

Professor Barbanti, an author of the study, commented “This trial continues to reinforce the results from previous studies which show that gammaCore appears effective for the acute treatment of migraine. Because it is well tolerated and is easy to use we hope that use of this therapy will help to decrease: patient’s reliance on medications that can cause side effects; safety concerns for some patients; and medication overuse complications.”

GammaCore is available through specialist headache and pain clinics across the EU and Australia. It is not yet available in the US.

(1)Pain relief defined as more than 50 percent reduction in visual analog scale (VAS)
(2)Barbanti et al. The Journal of Headache and Pain, 30th June 2015